Elron and CartiHeal: How Close Is the Contingent Consideration to Cash?
CartiHeal still sits on Elron’s books at $22.6 million, but the contract and the valuation framework both show that this is not a line item that should be treated as near-cash. The immediate leg has already been received, while the remaining value still depends on a long-dated commercial milestone and on a valuation that is sensitive to revenue and risk assumptions.
What Is Left of CartiHeal After the Cash Already Came In
The main article argued that Elron’s core gap is no longer between value and no value, but between value that has been created and value that is actually accessible for capital allocation. This follow-up isolates the CartiHeal line because it is too easy to see $22.6 million in the presentation and read it as near-cash. That is not what the contract says, and it is not what the valuation says either.
The sale to Smith & Nephew could bring Elron up to about $88 million, but the internal split matters more than the headline number. The immediate consideration amounted to about $48 million net of transaction costs, and roughly $5 million of that was placed in escrow for 12 to 18 months for indemnification purposes and was fully received during 2025. In other words, the cash leg of the deal has already moved almost entirely from contract to cash.
What remained at the end of 2025 was the harder piece: contingent consideration of up to about $40 million for Elron’s share. This payment is not tied to a normal schedule. It becomes payable only if Agili-C and additional products defined in the agreement generate net revenue of at least $100 million over 12 consecutive months, all within a 10-year window after closing. That is no longer a receivable. It is a layer of value tied to a commercial path.
| Layer | What is fixed in the contract or in the books | Why it matters |
|---|---|---|
| Immediate consideration | About $48 million net to Elron | This is the part that has already behaved like cash |
| Escrow deposit | About $5 million out of the immediate leg, fully received in 2025 | Even the interim piece has already been cleared |
| Contractual ceiling of the contingent leg | About $40 million for Elron’s share | This is the maximum number, not the accessible number today |
| Payment trigger | At least $100 million of net revenue over 12 consecutive months from Agili-C and additional products, within 10 years after closing | Payment depends on a commercial milestone, not just on time |
| Fair value at year-end 2025 | $22.561 million | This is the carrying value, not the cash receipt itself |
The chart captures the core debate. By the end of 2025, fair value had risen to $22.6 million, up from $18.4 million at the end of 2024 and $19.9 million at closing in January 2024. That is a real improvement, but it still leaves the asset at only about 56.5% of the contractual ceiling. Even after 2025, the company itself is not presenting this line as if payment were close to certain.
What Exactly Has to Happen Before This Number Becomes Cash
The most important point is that the trigger is not “general success” at CartiHeal. It is much narrower. The threshold is defined as net revenue of at least $100 million over 12 consecutive months, and only then does the contingent payment arise. That creates two kinds of distance from cash.
The first is operating distance. Even if sales are progressing, the business still has to cross a hard quantitative threshold within a continuous time window. The second is time distance. The agreement leaves a 10-year window from closing, so the fact that the right exists does not mean it is contractually close.
That is also why this line has to be read through a holding-company lens rather than an accounting-profit lens. Elron has already benefited from the immediate leg of the deal, including the release of the escrow deposit during 2025. What remains is not more cash waiting to be technically released. It is an economic right that still has to pass a commercial test at the acquirer.
In that sense, the right word here is neither “speculative” nor “certain.” The right word is contingent. There is real value here, but it still rests on a commercial event that has not yet been completed. Anyone who skips that distinction is blending measured value with accessible value.
Why $22.6 Million Is a Serious Number, but Not Near-Cash
In 2025, Elron recorded a gain of about $4.2 million from the change in the value of the contingent consideration asset. That matters, because it shows that the year-end 2025 valuation was more constructive than the year-end 2024 valuation. But it does not mean the company received another $4.2 million of cash, and it does not mean the payment is close in the same sense that cash or a deposit is close.
The proof is in the methodology itself. The contingent consideration asset was valued using a Monte Carlo model, with 50,000 iterations, an implied risk rate in the revenue forecast of about 12%, revenue volatility of 50.6%, a U.S. dollar risk-free rate of 3.78%, and a discount rate derived from BB-rated Healthcare debt in a range of 5.1% to 6.2%.
These are not technical footnotes. They tell the reader exactly what kind of asset this is. This is not debt with a known maturity. It is a value shaped by assumptions around sales trajectory, volatility, risk, and discounting. So the move from $18.4 million to $22.6 million in 2025 improves the accounting picture, but it does not remove the fact that this remains an assumption-sensitive asset.
Put simply: the number in the books is an economic estimate of what a future payment right is worth today, not a future payment that has already settled into something close to cash. That is why this line can improve reported earnings without answering the question of liquidity or capital-allocation flexibility.
Where CartiHeal Sits in Elron’s Value Map
The presentation actually makes this distinction quite clearly. In the financial snapshot slide, Elron presents the CartiHeal contingent consideration as a separate $22.6 million line within its effective value map. It is not absorbed into cash and other financial resources, which stand at $43.7 million, and it is not shown as if it were a regular part of portfolio holdings either.
The implication cuts both ways. On one hand, this line is too large to dismiss. At $22.6 million, it accounts for about 16.3% of the effective total value the company presents, and roughly half of the cash and other financial resources bucket. It is material. On the other hand, the presentation itself says that this amount represents the carrying value as of December 31, 2025 based on an external valuation. In other words, management is presenting it as a separate economic value line, not as cash that is already waiting to be deployed.
That is exactly where this continuation comes back to the main article’s thesis. If the right question in Elron is how much value is actually accessible to shareholders, CartiHeal sits in the middle: too large to ignore, but too contingent to merge into the liquid bucket without a mental discount.
Conclusion
The right reading of the CartiHeal line at the end of 2025 is not “paper value only,” but it is also not “almost cash.” It is a meaningful economic right that now carries a higher fair value in the books, while still depending on a clear commercial milestone and on a valuation model that is sensitive to assumptions.
Anyone looking at Elron through the accessible-value lens has to hold two thoughts at once. First, this is a real asset of meaningful size. Second, until the commercial milestone is actually met, it remains a contingent value layer: stronger than a hope line, weaker than cash. That difference between value and liquidity is still large enough to shape the entire Elron reading.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.